Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qingdao Vland Biotech CoSHSE:603739 +1.18%81 EBITDA Margin % is 10.90% as of Mar. 2026, which is 43% below its 10-year median of 19.08. GuruFocus rates SHSE:603739 with a GF Score™ of 81/100 and a GF Value™ of ¥14.54 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 940 Biotechnology companies, Qingdao Vland Biotech Co ranks better than 75.43% on this metric.
Qingdao Vland Biotech Co (SHSE:603739) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Qingdao Vland Biotech Co EBITDA Margin % Related Terms
Qingdao Vland Biotech Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603739 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Qingdao Vland Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qingdao Vland Biotech Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Qingdao Vland Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Qingdao Vland Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qingdao Vland Biotech Co (SHSE:603739) has a EBITDA Margin % of 10.90% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qingdao Vland Biotech Co and its competitors. This is 43% below median its historical median of 19.08. Over the past decade, Qingdao Vland Biotech Co's EBITDA Margin % has ranged from 10.75 to 19.57. According to the industry distribution chart, Qingdao Vland Biotech Co ranks #231 out of 940 companies in the Biotechnology industry, placing it in the top 24.6%.
Is Qingdao Vland Biotech Co's EBITDA Margin % too high?
Qingdao Vland Biotech Co's current EBITDA Margin % of 10.90% is 43% below median its 10-year median of 19.08. Over the past 10 years, this metric has ranged from a low of 10.75 to a high of 19.57. Based on the distribution chart, Qingdao Vland Biotech Co ranks #231 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Qingdao Vland Biotech Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qingdao Vland Biotech Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Qingdao Vland Biotech Co ranks #231 out of 940 companies for EBITDA Margin %. This places Qingdao Vland Biotech Co in the top 25% of its industry — outperforming the majority of peers. Historically, Qingdao Vland Biotech Co's own EBITDA Margin % has ranged from 10.75 to 19.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qingdao Vland Biotech Co and its competitors. Qingdao Vland Biotech Co's current EBITDA Margin % is 10.90%, which is 43% below median its own 10-year median of 19.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qingdao Vland Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Qingdao Vland Biotech Co (SHSE:603739) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.54, compared to a current price of ¥11.19 — trading 23% below its estimated fair value. The current EBITDA Margin % is 10.90%, which is 43% below median its 10-year median of 19.08. Qingdao Vland Biotech Co's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Qingdao Vland Biotech Co (SHSE:603739), the current EBITDA Margin % is 10.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qingdao Vland Biotech Co (SHSE:603739) Overvalued in 2026?
Based on GuruFocus' analysis, Qingdao Vland Biotech Co stock appears to be undervalued.
The current stock price of ¥11.19 is trading 23% below its estimated GF Value™ of ¥14.54.
GuruFocus considers Qingdao Vland Biotech Co to be Modestly Undervalued.
Key valuation signals for SHSE:603739:
EBITDA Margin %: 10.90% (43% below median its 10-year median of 19.08)
GF Value™: ¥14.54 vs. price of ¥11.19 (23% below fair value)
No single metric tells the full story. See the SHSE:603739 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qingdao Vland Biotech Co Ltd is a biotechnology company. The company is engaged in research and development of four main product categories which are enzymes, probiotics, vaccines and animal health products.
81GF Score
Get the complete analysis for SHSE:603739
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603739 has been successfully added to your 
